Dashboard
Manage Tickers

ACIU


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-reiterates-buy-on-ac-immune-maintains-8-price-target
BTIG Reiterates Buy on AC Immune, Maintain...
11/04/2025 17:02:00

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

ac-immune-q3-eps-020-beats-022-estimate-sales-1174m-miss-1520m-estimate
AC Immune Q3 EPS $(0.20) Beats $(0.22) Est...
11/04/2025 12:19:27

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by ...

ac-immunes-preclinical-data-on-brain-positron-emission-tomography-tracers-for-imaging-tdp-43-pathology-aci-19626-candidate-demonstrates-high-specificity-selectivity-for-target
AC Immune's Preclinical Data On Brain Posi...
10/24/2025 12:55:03

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative ...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/03/2025 17:06:08

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/03/2025 12:08:34

ac-immune-publishes-phase-1b2a-aci-35030-anti-ptau-results-in-ebiomedicine-rapid-durable-response-clean-safety-advancing-to-phase-2b-retain
AC Immune Publishes Phase 1b/2a ACI-35.030...
09/25/2025 11:07:53

btig-reiterates-buy-on-ac-immune-maintains-8-price-target
BTIG Reiterates Buy on AC Immune, Maintain...
09/08/2025 10:04:17

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

ac-immune-sharpens-pipeline-focus-with-30-workforce-reduction-and-chf-1271m-cash-extending-runway-to-end-of-q3-2027
AC Immune Sharpens Pipeline Focus With 30%...
09/04/2025 07:49:06

ac-immune-q2-eps-021-misses-017-estimate-sales-154m-miss-198m-estimate
AC Immune Q2 EPS $(0.21) Misses $(0.17) Es...
08/05/2025 11:25:18

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) b...

Core News & Articles
'FDA Clears First Blood Test Used In Diagn...
05/16/2025 17:32:57

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...

hc-wainwright--co-maintains-buy-on-ac-immune-lowers-price-target-to-12
HC Wainwright & Co. Maintains Buy on AC Im...
05/01/2025 12:49:29

HC Wainwright & Co. analyst Andrew Fein maintains AC Immune (NASDAQ:ACIU) with a Buy and lowers the price target from $1...

ac-immune-q1-eps-021-misses-020-estimate-sales-110m-beat-30067k-estimate
AC Immune Q1 EPS $(0.21) Misses $(0.20) Es...
04/30/2025 13:26:34

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) b...

hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on AC I...
04/03/2025 11:36:19

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

ac-immune-reports-further-interim-results-from-phase-2-trial-of-aci-7104056-active-immunotherapy-in-early-parkinsons-disease-says-repeated-immunizations-amplify-the-anti-a-syn-antibody-response
AC Immune Reports Further Interim Results ...
04/02/2025 10:04:28

Interim results show positive antibody responses were effectively induced against the target antigen at week 6 after 2 immuniza...

hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on AC I...
03/14/2025 12:29:05

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

ac-immune-fy24-eps-chf051-vs-chf064-yoy-contract-revenues-chf273m
AC Immune FY24 EPS CHF(0.51) vs CHF(0.64) ...
03/13/2025 11:16:00

ac-immune-aci-24060-was-generally-safe-and-well-tolerated-in-individuals-with-down-syndrome-with-no-serious-adverse-events-related-to-the-study-drug
AC Immune ACI-24.060 Was Generally Safe An...
12/10/2024 12:15:15

No cases of amyloid-related imaging abnormalities observed in this study population. Based upon these findings, AC Immune plans...

hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on AC I...
11/15/2024 11:39:21

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

sp-500-moves-lower-us-crude-oil-inventories-increase
S&P 500 Moves Lower; US Crude Oil Inventor...
11/14/2024 19:08:47

ac-immunes-active-immunotherapy-shows-antibody-responses-in-early-parkinsons-patients
AC Immune's Active Immunotherapy Shows Ant...
11/14/2024 15:32:49

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION